Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer

International Journal of Gynecological Pathology

Volumn 31, Issue 1, 2012, Pages 15-24

  Doçi, Colleen L ^a   Mankame, Tanmayi P ^a   Langerman, Alexander ^a   Ostler, Kelly R ^a   Kanteti, Rajani ^a   Best, Timothy ^a   Onel, Kenan ^a   Godley, Lucy A ^a   Salgia, Ravi ^a   Lingen, Mark W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Hypermethylation; Mutation; NOL7

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PROTEIN NOL7; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EXON; FEMALE; GENE CONTROL; GENE INACTIVATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; NUCLEOLUS; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WESTERN BLOTTING;

EID: 84856682205     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318220ba16     Document Type: Article

References (91)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Narisawa-Saito M, Yoshimatsu Y, Ohno S, et al. An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res 2008;68:5699-705.
3. Branca M, Giorgi C, Ciotti M, et al. Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer. J Clin Pathol 2006;59:1044-51. (Pubitemid 44570326)
4. Kaufmann AM, Backsch C, Schneider A, et al. HPV induced cervical carcinogenesis: molecular basis and vaccine development. Zentralbl Gynakol 2002;124:511-24. (Pubitemid 36717415)
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
6. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999;80:2008-18. (Pubitemid 29391289)
7. Lung ML, Choi CV, Kong H, et al. Microsatellite allelotyping of chinese nasopharyngeal carcinomas. Anticancer Res 2001; 21:3081-4. (Pubitemid 33051179)
8. Liao SK, Perng YP, Shen YC, et al. Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPCBM1) derived from a bone marrow metastatic lesion. Cancer Genet Cytogenet 1998;103:52-8.
9. Mutirangura A, Tanunyutthawongese C, Pornthanakasem W, et al. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer 1997;76:770-6. (Pubitemid 27379745)
10. Lim G, Karaskova J, Vukovic B, et al. Combined spectral karyotyping, multicolor banding, and microarray comparative genomic hybridization analysis provides a detailed characterization of complex structural chromosomal rearrangements associated with gene amplification in the osteosarcoma cell line MG-63. Cancer Genet Cytogenet 2004;153:158-64. (Pubitemid 39592149)
11. Takeshita A, Naito K, Shinjo K, et al. Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia. Cancer Genet Cytogenet 2004;152:56-60. (Pubitemid 38757378)
12. Amare Kadam PS, Ghule P, Jose J, et al. Constitutional genomic instability, chromosome aberrations in tumor cells and retinoblastoma. Cancer Genet Cytogenet 2004;150:33-43. (Pubitemid 38369245)
13. Fan YS, Rizkalla K. Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis. a summary of 154 cases. Cancer Genet Cytogenet 2003;143:73-9. (Pubitemid 36549009)
14. Batanian JR, Cavalli LR, Aldosari NM, et al. Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses. Mol Pathol 2002;55:389-93. (Pubitemid 35454514)
15. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002;99:3-9. (Pubitemid 34532956)
16. Giagounidis AA, Hildebrandt B, Heinsch M, et al. Acute basophilic leukemia. Eur J Haematol 2001;67:72-6. (Pubitemid 33010381)
17. Achuthan R, Bell SM, Roberts P, et al. Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. Cancer Genet Cytogenet 2001;130:166-72. (Pubitemid 33033235)
18. Shao JY, Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol 2000;17:1267-75.
19. Chen Z, Issa B, Brothman LJ, et al. Nonrandom rearrangements of 6p in malignant hematological disorders. Cancer Genet Cytogenet 2000;121:22-5. (Pubitemid 30665736)
20. Nakase K, Wakita Y, Minamikawa K, et al. Acute promyelocytic leukemia with del(6)(p23). Leuk Res 2000;24:79-81.
21. Nagai H, Kinoshita T, Suzuki H, et al. Identification and mapping of novel tumor suppressor loci on 6p in diffuse large B-cell non-Hodgkin's lymphoma. Genes Chromosomes Cancer 1999;25:277-83. (Pubitemid 29266697)
22. Nemani M, Bellanne-Chantelot C, Cohen D, et al. Detection of triplet repeat sequences in yeast artificial chromosomes using oligonucleotide probes: application to the SCA1 region in 6p23. Cytogenet Cell Genet 1996;72:5-8. (Pubitemid 26033980)
23. Jadayel D, Calabrese G, Min T, et al. Molecular cytogenetics of chronic myeloid leukemia with atypical t(6;9) (p23;q34) translocation. Leukemia 1995;9:981-7.
24. Hoyle CF, Sherrington P, Hayhoe FG. Translocation (3;6)(q21;p21) in acute myeloid leukemia with abnormal thrombopoiesis and basophilia. Cancer Genet Cytogenet 1988; 30:261-7.
25. Fleischman EW, Prigogina EL, Iljinskaja GW, et al. Chromosomal rearrangements with a common breakpoint at 6p23 in five cases of myeloid leukemia. Hum Genet 1983;64:254-6. (Pubitemid 13016621)
26. Mitra AB, Murty VV, Li RG, et al. Allelotype analysis of cervical carcinoma. Cancer Res 1994;54:4481-7. (Pubitemid 24273166)
27. Kersemaekers AM, Kenter GG, Hermans J, et al. Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998;79:411-17. (Pubitemid 28359741)
28. Huettner PC, Gerhard DS, Li L, et al. Loss of heterozygosity in clinical stage IB cervical carcinoma: relationship with clinical and histopathologic features. Hum Pathol 1998;29: 364-70. (Pubitemid 28231901)
29. Rader JS, Gerhard DS, O'Sullivan MJ, et al. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 1998;22:57-65. (Pubitemid 28217807)
30. Rader JS, Li Y, Huettner PC, et al. Cervical cancer suppressor gene is within 1 cM on 6p23. Genes Chromosomes Cancer 2000;27:373-9. (Pubitemid 30127625)
31. Mullokandov MR, Kholodilov NG, Atkin NB, et al. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 1996;56:197-205. (Pubitemid 26010400)
32. Hasina R, Pontier AL, Fekete MJ, et al. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene 2006;25:588-98. (Pubitemid 43164469)
33. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
34. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62. (Pubitemid 33741891)
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
36. Herman JG, Baylin SB. Gene Silencing in Cancer in Association with Promoter Hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
37. Zhang Z, Borecki I, Nguyen L, et al. CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 2007;67:11202-8. (Pubitemid 350248545)
38. Hagiwara K, Nagai H, Li Y, et al. Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. J Clin Exp Hematop 2007;47:15-8.
39. Zhang Z, Huettner PC, Nguyen L, et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 2006;25:5436-45. (Pubitemid 44330286)
40. Pesole G, Bernardi G, Saccone C. Isochore specificity of AUG initiator context of human genes. FEBS Lett 1999;464:60-2. (Pubitemid 30009749)
41. Bernardi G. Isochores and the evolutionary genomics of vertebrates. Gene 2000;241:3-17.
42. Bernardi G. The human genome: organization and evolutionary history. Annu Rev Genet 1995;29:445-76. (Pubitemid 26005351)
43. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82. (Pubitemid 17122132)
44. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 2000;16: 276-7.
45. Kanteti R, Yala S, Ferguson MK, et al. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol 2009;28:89-98.
46. Clark SJ, Harrison J, Paul CL, et al. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-97. (Pubitemid 24260626)
47. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-42. (Pubitemid 40916416)
48. Desmet FO, Hamroun D, Lalande M, et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37:e67.
49. Kralovicova J, Vorechovsky I. Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition. Nucleic Acids Res 2007;35:6399-13.
50. Buratti E, Chivers M, Kralovicova J, et al. Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 2007;35:4250-63. (Pubitemid 47260233)
51. Vorechovsky I. Aberrant 30 splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res 2006;34:4630-41. (Pubitemid 44590994)
52. Baev V, Daskalova E, Minkov I. Computational identification of novel microRNA homologs in the chimpanzee genome. Comput Biol Chem 2009;33:62-70. (Pubitemid 50254552)
53. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004;32:D109-11. (Pubitemid 38081615)
54. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol 2006;342:129-38.
55. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc Bioinform 2010;19:1-10. Chapter 12: Unit 12.
56. Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
57. Griffiths-Jones S, Saini HK, van Dongen S, et al. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8. (Pubitemid 351149713)
58. Mankame TP, Zhou G, Lingen MW. Identification and characterization of the human NOL7 gene promoter. Gene 2010;456:36-44.
59. Illingworth RS, Bird AP. CpG islands-[']A rough guide'. FEBS Letters 2009;583:1713-20.
60. Dong SM, Kim HS, Rha SH, et al. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001;7:1982-6. (Pubitemid 32994835)
61. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. (Pubitemid 37328947)
62. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22. (Pubitemid 46020844)
63. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41. (Pubitemid 43736116)
64. Moore DH. Cervical cancer. Obstet Gynecol 2006;107:1152-61.
65. Yu KJ, Rader JS, Borecki I, et al. CD83 polymorphisms and cervical cancer risk. Gynecol Oncol 2009;114:319-22.
66. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-4. (Pubitemid 24068340)
67. Dellas A, Moch H, Schultheiss E, et al. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. Gynecol Oncol 1997;67:27-33. (Pubitemid 27433324)
68. Davidson B, Goldberg I, Kopolovic J. Angiogenesis in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study. Int J Gynecol Pathol 1997;16: 335-8. (Pubitemid 27413523)
69. Lee JS, Kim HS, Jung JJ, et al. Angiogenesis, cell proliferation and apoptosis in progression of cervical neoplasia. Anal Quant Cytol Histol 2002;24:103-3.
70. Ozalp S, Yalcin OT, Oner U, et al. Microvessel density as a prognostic factor in preinvasive and invasive cervical lesions. Eur J Gynaecol Oncol 2003;24:425-8. (Pubitemid 37236572)
71. Ravazoula P, Zolota V, Hatjicondi O, et al. Assessment of angiogenesis in human cervical lesions. Anticancer Res 1996;16: 3861-64. (Pubitemid 27085062)
72. Triratanachat S, Niruthisard S, Trivijitsilp P, et al. Angiogenesis in cervical intraepithelial neoplasia and early-staged uterine cervical squamous cell carcinoma: clinical significance. Int J Gynecol Cancer 2006;16:575-80.
73. Hudelist G, Manavi M, Pischinger KI, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004;92:873-80. (Pubitemid 38251391)
74. Li W, Wang W, Si M, et al. The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. J Cancer Res Clin Oncol 2008;134: 1355-61.
75. Duenas-Gonzalez A, Lizano M, Candelaria M, et al. Epigenetics of cervical cancer: an overview and therapeutic perspectives. Molecular Cancer 2005;4:38.
76. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008;9: 465-76. (Pubitemid 351693975)
77. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-22.
78. Wu H, Coskun V, Tao J, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010;329:444-8.
79. Choi JK. Contrasting chromatin organization of CpG islands and exons in the human genome. Genome Biol 2010;11: R70.
80. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic?. Int J Biochem Cell Biol 2007;39:1432-49.
81. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta 2009;1792:14-26.
82. Zhou G, Doci CL, Lingen MW. Identification and functional analysis of NOL7 nuclear and nucleolar localization signals. BMC Cell Biol 2010;11:74.
83. Gardner LB. Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis. Mol Cancer Res 2010;8:295-308.
84. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 2008;33:385-93.
85. Roy SW, Irimia M. Intron mis-splicing: no alternative? Genome Biol 2008;9:208.
86. Hartmann B, Valcarcel J. Decrypting the genome's alternative messages. Curr Opin Cell Biol 2009;21:377-86.
87. Isken O, Maquat LE. Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev 2007;21:1833-56. (Pubitemid 47204924)
88. Scholzova E, Malik R, Sevcik J, et al. RNA regulation and cancer development. Cancer Lett 2007;246:12-23. (Pubitemid 44959406)
89. Chatterjee S, Pal JK. Role of 50- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 2009;101:251-62.
90. Chen JM, Ferec C, Cooper DN. A systematic analysis of disease-associated variants in the 30 regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006;120:1-21.
91. Lopez de Silanes I, Quesada MP, Esteller M. Aberrant regulation of messenger RNA 30-untranslated region in human cancer. Cell Oncol 2007;29:1-17. (Pubitemid 46535188)